Introduction
operative increase in vaginal fluid HIV titre, thereby greatly increasing the chances of sexual transmission of the virus [8, 9] .
The production of an HPV vaccine has prompted many developed countries to implement anti-HPV vaccination programmes which aim to target females prior to their first sexual exposure [10] . However, this will still leave large numbers of already infected women at risk, in addition to those infected with high-risk types of HPV not covered by the current vaccines. In developing areas like Africa the cost of such a vaccination programme, even with subsidies, is likely to be prohibitively expensive. Furthermore, there is also evidence to indicate that vaccination will be less effective in HIVpositive women [11, 12] .
For the foreseeable future it is clear that development of a non-surgical, preferably self-applied, treatment for HPV-related cervical dysplasia would be extremely valuable. This would have particular impact and benefit in low-resource settings where high levels of HIV infection can aggravate this condition.
We previously investigated the ability of HIV protease inhibitors to combat HPV infection and demonstrated that the antiretroviral drug lopinavir could stabilise the p53 protein and induce apoptosis of HPV-positive cervical carcinoma cells in vitro, albeit at higher doses than those achieved by oral administration [13] . These data indicated that lopinavir could potentially be used topically as an anti-HPV therapeutic. Prior to a clinical trial to test this new indication, we set out to further characterise how lopinavir works against HPV. In this regard we have used Fourier Transformation Infra Red spectroscopy to analyse the metabolic changes occurring in lopinavir-treated cervical carcinoma cells [14] and direct Raman spectroscopic imaging to identify the site of action of the drug in cells [15] . We now provide evidence to further support our initial observations and present data on the specific molecular mechanisms by which lopinavir works against HPV.
Methods

Cell culture
HPV16-positive SiHa and CaSki cells derived from cervical carcinoma were obtained from the American Type Culture Collection (Manassas, VA, USA) and were cultured at 37°C in a humidified atmosphere containing 5% CO 2 in RPMI-1640 medium (Invitrogen, Paisley, UK) supplemented with 10% fetal bovine serum (Sigma-Aldrich, Dorset, UK) and 2 mM L-glutamine (Sigma-Aldrich). Primary human foreskin keratinocytes (PHFKs) immortalised by retrovirally transducing with HPV16 E6 and E7 genes were grown in serum-free keratinocyte medium as recently described [16] .
Protease inhibitor
Lopinavir was provided as a kind gift by Abbott Laboratories (Abbott Park, IL, USA). A 20 mM working stock solution of lopinavir was prepared in DMSO (Sigma-Aldrich).
Derivation and use of pZsProSensor-1 transfected SiHa cells
The pZsProSensor-1 proteasome sensor vector (Clontech, Mountain View, CA, USA) was used to assess the ability of lopinavir to induce proteasomal inhibition and thus alter cellular protein levels. Linearised vector was used to stably transfect SiHa cells using Lipofectamine-2000 according to the manufacturer's recommendations (Invitrogen). Successfully transfected cells were selected using G-418-sulphate (Geneticin; Invitrogen).
pZsProSensor-1 transfected SiHa cells were seeded in duplicate wells of an eight-well slide flask (BD Biosciences, Bedford, UK). At 70% confluency, the growth medium was aspirated and replaced with growth medium supplemented with the non-specific proteasome inhibitor MG-132 as a positive control (Merck [Calbiochem], Nottingham, UK) at a final concentration of 10 µM for 4 h or lopinavir at a final concentration of 25 µM for 6 h. DMSO-treated control cells were also included. Following the incubation, cells were fixed in 2% paraformaldehyde and counter stained for 10 min using Hoechst nuclear stain at 0.5 µg/ml (SigmaAldrich). Expression of the green fluorescence reef coral protein (GFP) was detected through a standard FITC filter using an Olympus widefield microscope (Olympus, Southend-on-Sea, UK). Images were acquired using the Metavue software package (Metavue, Downington, PA, USA).
Analysis of changes in protein expression using antibody microarrays
The Panorama XPRESS Profiler-725 antibody microarray was used according to the manufacturer's instructions (Sigma-Aldrich; Additional file 1). In brief, HPVpositive SiHa cells were grown to 80% confluency before being treated for 6 h with either 25 µM lopinavir or DMSO control. Cells were harvested and total protein extracts from lopinavir and control DMSO-treated SiHa cells were fluorescently labelled with Cy3 fluorophore. 
RT-PCR
All reverse transcription (RT)-PCR work was carried out using an Applied Biosystems GeneAmp PCR System 2700 (Applied Biosystems, Carlsbad, CA, USA). The 'Cells-to-cDNA™ II Kit' (Invitrogen) was used according to the manufacturer's recommendations to synthesise complementary DNA (cDNA) from SiHa cells treated with either lopinavir (6 h at 25 µM) or DMSO control as previously described [13] . PCR was carried out in a 20 µl reaction volume containing 10 µl Biomix red (Bioline, London, UK), 0.5 µl each of ribonuclease L (RNASEL) forward primer (5′-AGC-AGA-CTC-TGG-AAG-CGT-GTT-T-3′) and reverse primer (5′-TGC-CAG-GTG-AGC-AGC-TTT-CTT-A-3′), and 2 µl cDNA sample. Cycle parameters were as follows: denaturing at 94°C for 5 min, followed by amplification for 32 cycles with denaturing at 94°C for 25 s, annealing at 53-57°C for 25 s, extension at 72°C for 25 s for 33 cycles followed by a final extension period of 3 min at 72°C. HPV16 E6 forward (5′-AAT-GTT-TCA-GGA-CCC-ACA-GG-3′) and reverse (5′-CAT-ACA-GCA-TAT-GGA-TT-CC-C-3′) test primers were used and GAPDH control PCR was carried out using the forward primer (5′-CAT-TGA-CCT-CAA-CTA-CAT-GGT-3′) and reverse primer (5′-TCG-CTC-GTG-GAA-GAT-GGT-GAT-3′).
Western blotting and antibodies used
Protein lysates were prepared from duplicate flasks treated with either lopinavir or DMSO control. Briefly, the growth medium was aspirated, and cells were washed with 1× phosphate-buffered saline (PBS) and detached from the culture flask using pre-warmed trypsin/EDTA (0.25%; Invitrogen) with incubation at 37°C/5% CO 2 . Trypsin was then neutralised by addition of 10 ml complete RPMI-1640 medium containing fetal bovine serum. A cell count was carried out and 5×10 5 cells were pelleted by centrifugation at 295 × g. Total protein from 5×10 5 cells, was lysed with 2× Laemmli sample buffer, and separated by 12% SDS PAGE for 2 h. Following this, proteins were transferred onto Hybond C Extra nitrocellulose membranes (Amersham Biosciences, Buckinghamshire, UK) using a semi-dry blotter (Whatman Biometra, Goettingen, Germany). Immunoprobing was carried out as described previously [13] , with the following primary antibodies, both supplied by Abcam (Cambridge, UK), polyclonal rabbit anti-RNASEL (ab32307) 1:500 in 1×PBS overnight at +4°C and mouse monoclonal anti-GAPDH (ab9484), 1:1,500 in 1×PBS, 1.5 h at room temperature. This was followed by washing and incubation with appropriate horse radish peroxidase-conjugated secondary antibodies at 1:2,000 in 5% milk powder in PBS for 2 h at room temperature. Swine anti-rabbit and rabbit antimouse horse radish peroxidase conjugated secondary antibodies were obtained from Dako, Cambridge, UK. Proteins were visualised using ECL and exposure to hyperfilm (Amersham Biosciences).
Analysis of growth and RNASEL expression in lopinavirtreated E6/E7 immortalised and control PHFKs
Stable E6/E7 immortalised PHFKs were treated with lopinavir at concentrations between 5 µM and 40 µM and cell growth assessed at 72 h by means of the CellTitre 96 ® AQ ueous One Solution Cell Proliferation Assay (AQ-96 assay; Promega, Southampton, UK). RNASEL protein levels were determined in lopinavirtreated E6/E7 immortalised PHFKs by western blotting as described.
siRNA silencing of RNASEL expression
Four different RNASEL-specific siRNA oligonuceotides (siRNA 1-4) plus AllStars and MAPK control oligonucleotides with no significant off-target homology were designed and obtained from Qiagen (Flexitube siRNA system; West Sussex, UK; siRNA-1, 5′-CCA-GAC-TAC-ACT-AGT-CCA-TAA-3′; siRNA-2, 5′-CAA-GTG-GAC-GAC-TAA-GAT-TAA-3′; siR-NA-3, 5′-CAG GAA-GTC-AAG-AGA-GAT-CTA-3′; siRNA-4, 5′-CCC-TAT-GAT-TGG-CAA-ACT-CAA-3′). These were transiently transfected into SiHa cells using Lipofectamine-2000 reagent according to the manufacturer's instructions (Invitrogen). RNASEL down-regulation was assessed by western blot 24 h post-transfection following 6 h of treatment with 25 µM lopinavir. SiHa cells were seeded in 96-well plates and transfected with siRNA-1 or the AllStars negative control as described above. Twenty four h post-transfection the growth medium was aspirated and replaced with fresh medium and initial cell viability determined by means of the AQ-96 assay. Growth medium in the remaining wells was supplemented with lopinavir to final concentrations of 20 µM, 25 µM, 30 µM or DMSO control. AQ-96 assay was then used to assess cell viability at each lopinavir concentration at 24, 48 and 72 h. Every data point was the result of three separate assays from three separately transfected wells.
Results
Lopinavir inhibits proteasome activity
Our previous studies have shown that lopinavir-treated cervical cancer cell culture lysates have decreased proteasome activity [13] . In order to verify this finding in vivo the SiHa HPV-positive cervical cancer cell line was stably transfected with the pZsProSensor-1 vector. This allows real-time monitoring of the proteasome in living cells, whereby addition of proteasome-inhibiting drugs results in accumulation of the fluorescent rapidly degraded proteasome target ZS-Green(GFP)/murine ornithine decarboxylase fusion protein encoded by the vector. The pZsProSensor-1 transfected SiHa cells were treated with lopinavir, the known proteasome inhibitor MG132 or a DMSO control. Lopinavir and MG132 produced a marked increase in detectable GFP levels when compared to DMSO-treated cells (Figure 1 ), demonstrating that, in a similar fashion to MG132, lopinavir has the ability to inhibit proteasomal activity. As the proteasome is a major cellular mechanism for regulating the concentration of a wide range of proteins, it follows that treatment of SiHa cells with lopinavir will result in changes in the cellular protein expression profile. Antibody microarray screening was therefore utilised in order to assess the extent of these changes on a number of proteins.
Lopinavir induces specific changes in protein expression in SiHa cells
Of the 725 proteins on the antibody array representing a wide range of biological pathways, 38 showed altered expression levels after lopinavir treatment (Table 1) . Only three showed a reduction in levels whilst the remaining proteins all showed a drug-induced increase. A detailed discussion of the potential significance of all of these changes is beyond the scope of this communication. However, for information, we have tabulated the main functions currently ascribed to these proteins based on published literature searches. Significantly, several classical apoptosis-related proteins were up-regulated such as annexin 5, tumour necrosis factor, active caspase 3, Tp63 and Tp53. This finding was relevant as it substantiated our previous work where we demonstrated apoptotic cell death in HPV-positive SiHa cells following lopinavir treatment. Of particular interest, however, was the upregulation of the interferon-induced RNASEL since it had previously been reported to have antiviral activity [17, 18] . Figure 2A highlights the differential RNASEL antibody array protein signal we obtained from lopinavir versus control DMSO-treated SiHa cells. This was confirmed by immuno-probing a western blot of proteins isolated from these cells where a significant up-regulation of RNASEL was observed ( Figure 2B ). Since RT-PCR demonstrated no obvious difference in the RNASEL messenger RNA levels between replicate DMSO-treated control and lopinavirtreated SiHa cells ( Figure 2C ) these data support the hypothesis that lopinavir inhibits proteasomal degradation of the RNASEL protein and this was prioritised for further study.
Lopinavir induces both dose-and time-dependent changes in RNASEL protein levels in SiHa cells but has no effect on CaSki cells
To further investigate the association between lopinavir treatment of SiHa cells and variations in RNASEL protein levels, both dose-and time-dependent effects were assessed. Lopinavir produced a clear dose-dependent increase in RNASEL levels over a range of concentrations tested ( Figure 3A) . This was repeated on a second HPV-positive cervical carcinoma cell line, CaSki, which we had previously reported as refractory to lopinavir treatment [13] . No evidence of RNASEL upregulation was observed in CaSki cells, which is interesting in light of the fact that they express much higher levels of HPVT16 E6 ( Figure 3B) . SiHa cells were then tested further by treating with a fixed concentration of lopinavir (25 µM) and RNASEL levels assessed at various time points ( Figure 3C ). There was a clear timedependent increase of RNASEL protein over the 2 h intervals up to 12 h of treatment. This was followed by drop in level at 24 h. However, as the housekeeping GAPDH control signal also dropped at 24 h this was likely due to the previously reported toxic effects of 25 µM lopinavir at this time point [13] .
Lopinavir induces selective toxicity against E6/E7 immortalised PHFKs with an associated up-regulation of RNASEL
The SiHa cervical carcinoma cell line has proved itself as a useful laboratory tool and has been used These proteins are known to be subject to proteasomal degradation. extensively by many groups over the last 40 years. It is, however, a fully transformed cell line and if lopinavir is to be used as a topical treatment for the precancerous target cells that are present in HPV-related cervical dysplasia, then cells more representative of the intended cell type should also be tested. For this reason it was decided to investigate the effects of lopinavir against HPV16 E6/E7 immortalised primary human foreskin keratinocytes (PHFKs) and control PHFKs which were treated over a 72 h period using a dose range of 5-40 µM ( Figure 4A ). This demonstrated greatly increased toxicity of lopinavir for E6/E7-expressing PHFKs when compared to normal (non-transduced) PHFKs. While the growth of normal PHFKs progressed relatively uninhibited up to concentrations of 25 µM, both SiHa and E6/E7 PHFKs showed markedly reduced growth. Furthermore, RNASEL protein levels in E6/E7 transduced PHFKs also increased, albeit at a slower rate than was observed in SiHa cells ( Figure 4B ). While 25 µM lopinavir treatment caused a peak RNASEL signal in SiHa cells after 8 h and a subsequent drop after 24 h (Figure 3B ), E6/E7-expressing PHFKs peaked at 48 h followed by a subsequent drop after 72 h ( Figure 4B ).
siRNA-targeted silencing of RNASEL reduces the toxicity of lopinavir in SiHa cells
An extensive reduction in RNASEL protein level was seen following transfection with four different RNASEL targeting siRNAs and siRNA oligonucleotide 1 (siRNA-1) was found to be the most effective ( Figure 5A ) and was used in subsequent experiments Cells were harvested at the times indicated and immuno-probed with RNASEL and GAPDH antibodies. Lopinavir produced a time-dependent increase in RNASEL protein levels, with a peak occurring after approximately 12 h incubation with lopinavir. This peak was followed by a decrease in protein levels observed at 24 h.
At a 25 µM concentration of lopinavir, siRNA-1 transfected cells showed a significant (P<0.05 at 72 h) growth advantage over AllStar transfected cells ( Figure 5D ), whereas at 30 µM there was equivalent growth inhibition ( Figure 5E ). This finding is consistent with the observed toxic effects of lopinavir on E6/E7 immortalised and control PHFKs shown in Figure 4A where the growth of normal PHFKs was unaffected at concentrations up to 25 µM lopinavir, whereas at 30 µM they were inhibited by this treatment. The data from the RNASEL silencing experiments thus provides strong evidence that this protein plays a role in the observed selective toxicity of lopinavir in HPV E6/E7 cells up to an optimum concentration of 25 µM.
Discussion
Our data are the first to show that the HIV protease inhibitor lopinavir induces an increase in the levels of the RNASEL protein in HPV-positive cervical carcinoma cells and in stable HPV16 E6/E7 transfected human keratinocytes. Lopinavir was also shown to have enhanced toxicity against E6/E7 immortalised PHFKs when compared to normal PHFKs and our results are consistent with RNASEL contributing to this selective toxicity. In agreement with the results shown in Figure 1 , other groups have shown lopinavir can induce selective inhibition of the proteasome and this ability is thought to play a significant role in the anti-HIV effects of this, and other related compounds [19] [20] [21] [22] . In addition to HIV, many viruses including HPV, have been shown to subvert/hijack the activity of the host proteasome in order to eliminate proteins that would be detrimental to viral persistence [23] . In HPV-infected cells the E6 and E7 oncoproteins are largely responsible for this activity, whereby they signal the destruction of selected cellular proteins (for example, p53 and Rb) in order to execute the viral life cycle [24] .
Based on these observations, we opted to use antibody array screening of lopinavir-treated SiHa cells to analyse changes in protein expression following this treatment. This identified a whole range of cellular proteins that were up-regulated (Table 1) , including Tp53 which is consistent with our previously reported findings [13] . Indeed, as we have discussed, lopinavir induced changes in the levels of several other apoptosis-related proteins and it is also significant that the majority of the proteins listed in Table 1 are known to be regulated by proteasomal degradation. On this point, an interesting finding was the observed lopinavir-induced down-regulation of GFAP which is known to be capable of inhibiting the proteasome [25] . Since p53 is a target of high-risk HPV E6, we searched the Virus Molecular INTeraction (VirusMINT) database [26] for any other known E6 and E7 targeted proteins which are affected by lopinavir treatment (Table 1) . At this time, only Tp53 is a confirmed target of high-risk HPV.
Given that SiHa cells are a fully malignant cell type, we opted to investigate the toxicity of lopinavir against E6/E7 immortalised and normal control PHFKs. This showed that at a concentration of 25 µM, lopinavir upregulated RNASEL expression in the E6/E7 cells which were much more susceptible to lopinavir-induced cell death than control PHFKs. At higher concentrations of drug, this selectivity was lost and these data indicate that lopinavir has a good therapeutic index for E6/E7 PHFKs at concentrations up to 25 µM. Since these cells are not transformed it is most likely that this is due to the ability of lopinavir to activate apoptotic antiviral systems which are suppressed by E6/E7.
Curiously, it is known that HIV patients receiving oral lopinavir as part of HAART do not show enhanced clearance of HPV-related lesions [27] . On this point, it is noteworthy that the concentration of lopinavir found in the vaginal fluid of HIV patients taking oral Kaletra is <2 µM [28] , which has been discussed in our previous study [13] .
In order to address the issue of whether the observed HPV-specific toxicity of lopinavir is related to its ability to block RNASEL degradation by E6/E7, siRNA RNASEL gene silencing experiments were carried out in lopinavir-treated SiHa cells. These experiments showed that, at the optimum therapeutic dose range of 25 µM, lopinavir had much reduced toxicity in RNA-SEL siRNA transfected SiHa cells when compared to the same cells transfected with AllStar control siRNA. These results support the hypothesis that the selective toxicity of lopinavir in HPV E6/E7 expressing cells is at least in part mediated by up-regulated expression of the RNASEL protein.
It is also notable that our results support the conclusion that HPV can compromise the antiviral activity of RNASEL. The observation that CaSki cells are insensitive to lopinavir [13] and do not up-regulate RNASEL is significant since CaSki cells express much higher levels of E6 than do SiHa ( Figure 3B ). Indeed, investigation of the effects of E6 on RNASEL toxicity is the subject of our continued work.
Thus, the logical conclusion from these observations is that inactivation of the RNASEL response by HPV infection of the cervix could lower host antiviral defences and increase the likelihood of infection with other viruses. This is highly significant when considered with the previously discussed findings that genital HPV infections can predispose to increased risk of HIV transmission in both men and women [29, 30] .
In conclusion, our data support the potential use of lopinavir as a topical, self-administered treatment for HPV-related cervical dysplasia. If successful, this treatment would be particularly useful in low-resource countries which lack cytology screening and surgical services, and where HIV infection is often a significant additional complication. With current pricing strategies, anti-HPV vaccines are not an option in such settings, and as previously discussed, they will most likely have reduced efficacy in HIV-positive women. Furthermore, in view of the observation that infection with HPV can enhance the sexual transmission of HIV in both men and women [29, 30] , this clearly indicates that a simple, non-surgical treatment for HPV-related precancerous lesions may not only reduce the burden of cervical cancer but may also reduce the chances of HIV transmission.
